GlaxoSmithKline Consumer Healthcare reports sales of Rs. 1,136 cr in Q2
The reported net sales decline of 1.3% got impacted due to one off accounting adjustment sitting in the base and impact of change in accounting standard (IndAS).
The PBT declined by 15% on account of one off exceptional income of Rs. 56 Crores sitting in the base year.
The Company’s HFD market share increased by 0.6% during the quarter.
The HFD category grew by 0.8% value during Jan – Sept ’16, led by GSKCH +1.2%. Market share for GSK Consumer healthcare has grown in volume at 66.4% (up by 1%) & value at 58.3% (up by 0.5%). The company continues to invest in A&P at 13% of Sales (reported 11% driven by media buying efficiencies).
In a statement, Manoj Kumar, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “Despite the subdued demand in the FMCG sector, we have gained share in the HFD category. We continue to improve consumer’s experience with new products like Horlicks Marie, our biggest launch in the foods category.”
“We emphasized on our access strategy with the re-launch of Rs.5 pack of base Horlicks & Boost to ensure that our products are within the easy reach of our larger consumer base. Focus on science, innovation and customer, remains our key differentiator and helps us to stay ahead in the category. Our outlook for the upcoming quarter’s remains positive,” added Kumar.
Image:http://india-consumer.gsk.com/
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
